Highlights and Quick Summary
- Equity Repurchase (Common, Net) for the quarter ending June 30, 2023 was $24.9 Million (a -13.57% decrease compared to previous quarter)
- Year-over-year quarterly Equity Repurchase (Common, Net) increased by 35480.0%
- Annual Equity Repurchase (Common, Net) for 2022 was $37.4 Million (a -76.31% decrease from previous year)
- Annual Equity Repurchase (Common, Net) for 2021 was $158 Million (a -35.95% decrease from previous year)
- Twelve month Equity Repurchase (Common, Net) ending June 30, 2023 was $91 Million (a 37.48% increase compared to previous quarter)
- Twelve month trailing Equity Repurchase (Common, Net) increased by 32868.84% year-over-year
Trailing Equity Repurchase (Common, Net) for the last four month:
| 30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
|---|---|---|---|
| $91 Million | $66.2 Million | $37.4 Million | $276 Thousand |
Visit stockrow.com/DYN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Equity Repurchase (Common, Net) of Dyne Therapeutics, Inc.
Most recent Equity Repurchase (Common, Net)of DYN including historical data for past 10 years.Interactive Chart of Equity Repurchase (Common, Net) of Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. Equity Repurchase (Common, Net) for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $24.91 | $28.82 | – | – | – |
| 2022 | $37.2 | $0.07 | $0.1 | $0.02 | $37.39 |
| 2021 | $0.09 | $0.46 | $0.03 | $157.25 | $157.82 |
| 2020 | $-1.06 | $247.48 | – | – | $246.42 |
Business Profile of Dyne Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology